Kon Fung Chan Net Worth

The estimated Net Worth of Kon Fung Chan is at least $5.4 Milión dollars as of 15 October 2004. Kon Chan owns over 293,190 units of Immutep stock worth over $2,469,332 and over the last 20 years Kon sold IMMP stock worth over $2,931,900.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kon Chan IMMP stock SEC Form 4 insiders trading

Kon has made over 1 trades of the Immutep stock since 2004, according to the Form 4 filled with the SEC. Most recently Kon sold 293,190 units of IMMP stock worth $2,931,900 on 15 October 2004.

The largest trade Kon's ever made was selling 293,190 units of Immutep stock on 15 October 2004 worth over $2,931,900. On average, Kon trades about 293,190 units every 0 days since 2004. As of 15 October 2004 Kon still owns at least 953,410 units of Immutep stock.

You can see the complete history of Kon Chan stock trades at the bottom of the page.

What's Kon Chan's mailing address?

Kon's mailing address filed with the SEC is FLAT B 16TH FL., 132 BROADWAY MEI FOO SUN CHUEN, KOWLOON, K3, 00000.

Insiders trading at Immutep

Over the last 21 years, insiders at Immutep have traded over $3,152,820 worth of Immutep stock and bought 15,000 units worth $128,330 . The most active insiders traders include Kon Fung Chan, Frederick W Wackerle a Levi Hong Kaye Lee. On average, Immutep executives and independent directors trade stock every 132 days with the average trade being worth of $138,215. The most recent stock trade was executed by Frederick W Wackerle on 17 November 2005, trading 10,000 units of IMMP stock currently worth $65,800.

What does Immutep do?

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Complete history of Kon Chan stock trades at Immutep

Immutep executives and stock owners

Immutep executives and other stock owners filed with the SEC include:

• Marc Voigt,
  CEO, MD, CFO, Chief Bus. Officer & Exec. Director
• Dr. Frederic Triebel M.D., Ph.D.,
  Chief Scientific Officer & Chief Medical Officer
• Deanne Miller LLB,
  COO, Gen. Counsel & Joint Company Sec.
• Shengfei Fang,
  Fin. Director & Assistant Company Sec.
• Christian Mueller,
  Director of Clinical Devel. & Regulatory Affairs
• Indira Naidu,
  Joint Company Sec.
• David Martin Fleet,
  Director
• Donald Francis Sinex,
  Director
• Harvey R Md Colten,
  Director
• Cecilia Chan,
  Executive Vice President
• Gary C Parks,
  Treasurer, Secretary and CFO
• Levi Hong Kaye Lee,
  Director
• Ching Yin Judy Lau,
  Director
• Frederick W Wackerle,
  Director
• Carol Ann Olson,
  VP & Chief Medical Officer
• T Stephen Thompson,
  CEO and President
• Eric L Sorkin,
  Director
• Kon Fung Chan,
  10% owner
• Daniel M Schmitt,
  VP, Licensing & Comm Dev.
• Deborah Zonies,
  VP & General Counsel